Between 2 and 3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally each year.
1 in 5 Americans will develop skin cancer by the age of 70.
More than 2 people die of skin cancer in the U.S. every hour.
Clearly the world needs a much better early skin cancer screening technology.
MedX Health Corp. (TSXV: MDX) is a leading medical device and software company focused on the early detection of skin cancer. MedX has approvals in 35 countries and distribution agreements in place for its key skin cancer diagnostic products – SIAscope and DermSecure™ telemedicine platform.
Following on from MedX’s regulatory approval and distribution agreement in Brazil (read here), the Company recently announced an exciting exclusive distribution agreement to launch SIAscopy on DermSecure™ in Mexico with EMC LABS, S.A.P.I. DE C.V., operating as MedX Mexico. MedX Mexico plans to launch an aggressive ease-of-access skin scanning/assessment program throughout Mexico, using MedX’s SIAscopy on DermSecure™ Telemedicine platform. MedX Mexico will cover all the upfront costs for application for regulatory approval in Mexico, all marketing costs, and will utilize their large-scale distribution network in Mexico.
MedX Mexico’s, President and CEO, Carlos Vizcaino, states:
“There is a significant opportunity for MedX’s rapid skin assessment technology in Mexico, as skin cancer is a very common type of cancer in Mexico……MedX’s SIAscopy on DermSecure™ Telemedicine platform and advanced SIAscopy imaging technology is a perfect solution to assist dermatologists and physicians in the diagnosis process for early detection of melanoma.”
Masterplan
MedX Health’s masterplan is to continue to rollout distribution agreements with partners globally. So far Brazil and now Mexico are underway. MedX’s revolutionary skin cancer detection device is approved in the USA, Canada, Brazil, Australia, New Zealand, the European Union, Turkey, and many other places. In total MedX’s device has achieved regulatory approval in 35 countries. This means we can expect further distribution agreements in the future to many of the above countries. The potential for future revenues is enormous.
MedX’s business model is similar to Software as a Service (SaaS) companies. The revenue model uses front-end hardware sales coupled with recurring “platform” revenue based on a minimum number of screens per device (360/year at $10/image).
2019 revenues were only small at C$860,248, and 1st quarter 2020 C$95,544, as the Company was impacted by COVID-19 and had yet to ramp up distribution as is now occurring in 2020. For a guide on where revenues are headed the next two years the Beacon Securities report is most useful.
The report’s analysts says MedX has strong visibility on initial orders from the MedX Brazilian distribution partner, that could result in $8 million of hardware sales over the next 2 years and a run-rate of $14 million of high margin, recurring platform revenue by the end of FY21. Given that MedX currently trades on a market cap of C$24 million, the C$14 million, if achieved, would mean MedX would trade on a 2022 market cap/sales ratio of only 1.7. Beacon Securities rates MedX Health a ‘buy’ with a Price Target of C$0.45. Given the stock currently trades at C$0.135, the C$0.45 price target represents a very significant upside of 233% or a 3.3 fold gain.
Closing remarks
It is very clear to me that the market is yet to wake up to the potential very large boost in revenues that MedX is working to achieve, now with distribution agreements in both Brazil and Mexico.
Detecting skin cancer is an enormous global need and MedX is working hard to fill this need. MedX has the right device and approvals in 35 countries. All that is needed now is further distribution agreements and revenue to flow. The opportunity for investors to get in early on such a great company with a very bright future still exists. I would not recommend waiting too long as the cheap valuation is unlikely to last long, especially as further new deals are announced.
Posted by AGORACOM-JC
at 5:42 PM on Wednesday, August 12th, 2020
The call, led by Chairman Terry Booth, CEO Adam Cegielski and Scientific Advisor Dr. Sandra Stoddard PhD, formally announced the Company’s expansion in to the K-12 education sector, drawing attention to the great impact that professional-lead neuro-vision therapy and training can have on learning and reducing the global education gap
By targeting K-12, the company is aiming to get Binovi into over 15,000 schools in Canada and over 130,000 schools in the United States
Toronto, New York – August 12, 2020 – Binovi Technologies Corp., (Binovi) (TSXV:VISN) | (OTC:BNVIF), a leader in neuro-vision performance technology, today shared the key highlights from its Investor Conference call held Tuesday August 11th, 2020. The call, led by Chairman Terry Booth, CEO Adam Cegielski and Scientific Advisor Dr. Sandra Stoddard PhD, formally announced the Company’s expansion in to the K-12 education sector, drawing attention to the great impact that professional-lead neuro-vision therapy and training can have on learning and reducing the global education gap.
“The plan in place for the next year truly exemplifies the shift necessary to grow the Binovi Platform to a Global and Noble product. Our team has worked tirelessly to develop and drive the commercial success of the platform, and the expansion into k-12 education is a natural evolution of the company’s capabilities to enhance cognitive performance through vision training. The efforts reflect our long-term business strategy and goals,” commented Terry Booth, Binovi Chairman.
Key Highlights from Binovi Investor Call:
Market Potential
Terry: “By targeting K-12, we’re aiming to get Binovi into over 15,000 schools in Canada and over 130,000 schools in the United States.”
Sandra: “I think [the rate of adoption] will skyrocket once we have the data in place about using Binovi. There’s so much research that proves already that vision therapy does improve developmental domains, the reading skills of kids, but we want to be able to show unequivocally that Binovi Touch works.”
Adam: “There are a lot of good tools out there, and there are a lot of companies that have built tools and they’re selling their tools and they’ve done a good job on how they’ve built those tools and how they market those tools; they’ve been very focused and they’ve had market penetration success; We are a platform, a platform that can continuously add technology and expand. We’ve taken a more global approach in our product development.”
Education Impact
Sandra: “Reading at grade level by grade 3 is the highest predictor for high school completion. We know that when kids complete high school it leads to so many more positive outcomes for them. In our field, we know that when kids don’t graduate, it’s close to 90% of kids that aren’t graduating weren’t able to read by grade 3.”
Sandra: “Close to 80% of children that do have learning disabilities in the area of reading meet the criteria for accommodation convergence problems, which literature has shown to lead to issues with accuracy, comprehension, or fluency. We also know that the earlier that we can intervene with individuals, the earlier we can remediate the problem.”
Sandra: “I am incredibly excited about utilizing this platform to really confirm that, if we can intervene early and help kids utilize vision therapy and remediate the vision difficulties, I’d like to be able to prove that it does have an impact on reading performance. If we can demonstrate that intervening early with these individuals can not only improve their ready ability but also improve their ability to attend; lots of kids that have been diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) also have vision deficits, so the potential for to globally impact these young kids, not only from a reading perspective but from those attentional learning skills needed to be successful in life, this could be a game-changer for the education field.”
Global Impact
Adam: “Over a billion people suffer from binocular issues.”
Terry: “This is way bigger than cannabis; this is a huge opportunity for investors but also schools, kids, and athletes. This is something that affects millions of people.”
Economic impact
Sandra: “Increasing the number of high school graduates in Canada by just 1% can save $7.7B; we see that not completing high school leads to higher rates of incarceration, lower levels of employment, more health issues.”
Ease of Use
Terry: “Vision training can take as little as 15 minutes per day, supported at home.”
Adam: “The infrastructure exists with support staff in schools and the goal is to use technology to link in with someone at the schools to be a centralized person within the school to work with teachers and simplifying the implementation.”
Sandra: “Having been through a walkthrough of the Binovi Platform for vision therapy, I can say that it is very very easy to use. We’d probably have to make some changes to make it motivational to some of the younger kids, but it is easy to use, all platforms can be integrated into the Binovi Platform, so my data collection can be tracked using Binovi. iPads are familiar, so I can easily see it being adopted into the education system.”
Telehealth
Adam: “Telehealth is a significant reality in the North American marketplace today; it’s really a by-product of the advancement of technology and where we are today. We’ve traditionally been dealing with technology solutions that are impacting us in different ways. I think it’s a unique opportunity now to converge all this technology into one spot. The education environment has never seen such dramatic changes in such a short period of time.”
Adam: “Our CTO, Dr. Mithani, has been working extensively on understanding the necessary pieces that Binovi has to have in place, and to be honest we’ve been on top of this substantially even before COVID hit. We’ve been working towards these things.”
Terry: “In our early discussions, Adam already had the plans in place to make sure that this was available through a telehealth platform. We needed to make this available to people from their homes, and it’s become a far bigger piece of the puzzle.”
“Binovi has the opportunity to be the global leader in how we shape the vision and brains of future generations. Looking ahead, we have implemented a number of initiatives to ensure the Company’s continued growth, and to generate the best possible performance results during these unique times. We are fortunate to support dedicated product users, while relying upon the experience and knowledge of our team to lead us to the next summit,” added Adam Cegielski, Binovi CEO
The expansion into education is in stride with the Company’s “Global and Noble” initiatives directed towards accelerating the development of reading fundamentals.
The company also announces today that it anticipates additional delays in filing its financial statements for the year ended February 29, 2020 and the related management’s discussion and analysis (“MD&A”) and certifications (the “Annual Filings”). The Company has filed an application with the relevant securities authorities requesting that they issue a management cease trade order (an “MCTO”).
As previously announced, the Company had relied upon the blanket relief provided by the Canadian Securities Administrators (the “CSA”) in response to the COVID-19 pandemic to extend the filing deadline for the Annual Filings. Due to ongoing complications in collection of certain required data and documentation to complete the audit of the Company caused by COVID-19, the resulting restrictions in travel and limited access to facilities, the Company does not expect to be able to file the Annual Filings by their respective extended deadlines. The Company will work with its auditors to complete the audit of the Company’s consolidated financial statements, and expects to file the Annual Filings by August 31, 2020.
Pursuant to National Policy 12-203 Management Cease Trade Orders (“NP 12-203”), the Company is requesting that an MCTO be issued. If granted, the MCTO will restrict all trading by the Company’s Chief Executive Officer and Chief Financial Officer, and such other directors, officers and persons as determined by the applicable regulatory authorities, in the Company’s securities. There is no certainty that such order will be granted.
An MCTO will not affect the ability of persons other than the directors, officers and insiders to trade in the Company’s securities. An MCTO will remain in effect until the Annual Filings are filed or until it is revoked or varied. If an MCTO is not granted, the applicable regulatory authorities may issue a cease trade order against the Company for failure to file the Annual Filings within the prescribed time period.
Until the Company completes the Annual Filings, the Company will comply with the alternative information guidelines set out in National Policy 12-203 – Cease Trade Orders for Continuous Disclosure Defaults for issuers who have failed to comply with a specified continuous disclosure requirement within the times prescribed by applicable securities laws. The guidelines, among other things, require the Company to issue bi-weekly default status reports by way of a news release so long as the Annual Filings have not been filed.
Binovi is a best-in-class neuro-visual performance platform designed to test, analyze, track, and report on individual cognitive performance. Binovi combines hardware, software, specialized expert knowledge, and unique data insights to deliver customized, one-on-one training and learning protocols ideal for K-12 Students, Vision Care Specialists, and Sports Performance testing and training. Designed for vision optimization and the enhancement of skills related to cognitive performance, Binovi provides measurable results in less time, and with less effort. Binovi is currently used in over 1,500 locations across 20 countries.
Certain statements contained in this news release constitute “forward-looking information” as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company’s financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company’s financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company’s continuous disclosure filings filed under the Company’s profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 5:25 PM on Wednesday, August 12th, 2020
(TSXV: MTRX)
WHY LOOP INSIGHTS?
What if you could receive the same personalization and experience you get from online shopping, but in brick and mortar stores? Loop Insights is doing just that.
Brick and mortar retail isn’t going anywhere, but it does need to adapt to offer better in-store customer experiences. Loop Insights solves a significant problem for traditional retailers – big and small – who are losing customers to e-commerce retail.
All e-commerce sites have easy access to company-wide connectivity, real-time insights, and personalized marketing. What Loop is doing is creating those same tools for physical retail, whether it is a restaurant, hotel, casino, store, or stadium.
Loop’s proprietary internet of things (IoT) device, Fobi, makes it all happen. It can be installed in minutes using an API or hardware solution, making Loop’s services ultimately scalable no matter what infrastructure is currently set up in the store.
NORTH AMERICA’S BIGGEST MOBILE COMPANIES BELIEVE
SEEING IS BELIEVING
Now that you have an understanding of the magnitude of the problem and the disruptive power of LOOP, you need to see it for yourself. Watch this short but powerful videos demonstrating how LOOP is being applied across different verticals to solve brick and mortar retail problems.
Posted by AGORACOM-JC
at 4:13 PM on Tuesday, August 11th, 2020
Announced its strategic expansion into pre-K-12 Education. The expansion is in stride with the Company’s “Global and Noble” initiatives directed towards accelerating the development of reading fundamentals.
Cognitive literacy skills for students of all abilities from pre-K to grade 3, with continued reading comprehension activities to grade 12, will be advanced through technology-driven vision training protocols
The company is positioned to leverage the flexibility of the Binovi Platform and empower students and teachers globally in this new post COVID-19 world
Toronto, New York – August 11, 2020 – Binovi Technologies Corp., (Binovi) (TSXV:VISN) | (OTC:BNVIF), a leader in neuro-vision performance technology, announces its strategic expansion into pre-K-12 Education. The expansion is in stride with the Company’s “Global and Noble” initiatives directed towards accelerating the development of reading fundamentals. Cognitive literacy skills for students of all abilities from pre-K to grade 3, with continued reading comprehension activities to grade 12, will be advanced through technology-driven vision training protocols. The company is positioned to leverage the flexibility of the Binovi Platform and empower students and teachers globally in this new post COVID-19 world.
“Expanding our Binovi vision therapy technology into the field of education is the most exciting development I have seen. Research has already proven that binocular vision problems can interfere with a student’s ability to read. In fact, 80% of children diagnosed with a learning disability meet the criteria for visual accommodation and vergence problems. Knowing this, our Binovi Platform has been designed to provide early-intervention vision therapy activities to help increase reading abilities by grade three, which is the strongest predictor of high school completion and other positive life outcomes. If we can integrate our Binovi platform into the school system and have it accessible to all children as early as kindergarten, the impact of being able to detect and remediate early vision deficits, that are impeding children’s ability to read successfully by grade 3, could be a game changer,” said Terry Both, Executive Chairman, Binovi Technologies
The global education smart technology industry is growing significantly with abundant opportunities. North America plays a huge role in the development of this technology, which helps in the adoption of new learning solutions across various end-user segments. The goal of Binovi is to provide the global education sector with the best vision assessment and development tools to assist students to achieve all that they are capable. New learning opportunities are emerging as students engage with a new generation of smart technology; with smart classrooms becoming the norm, students have instant access to performance and cognitive tools that can supplement their learning success.
There is approximately 15,000 k-12 schools within Canada and over 130,000 schools within the USA. Binovi hopes to penetrate this North American education sector with our product offering and for each school we are able to license the revenue would be approximately $50k to 100k per school based upon our current pricing structure.
“Vision extends well beyond the realm of eyesight and is a fundamental component of cognition. Educators assume that each child enters the educational system with adequate visual abilities, but all too often that is not the case. Binovi technology is poised to help level the playing field among students,” commented Dr. Leonard Press, Chief Scientific Officer, Binovi Technologies
Blending personalized, online, student-driven instruction with offline, teacher-delivered lessons and activities, Binovi strives to accelerate the development of both fundamental literacy skills and higher-order thinking skills through adaptive learning paths. With a range of instructional and motivating resources, Binovi for Education will engage students in their learning success. Additionally, progress monitoring, actionable data, and scripted lessons will empower teachers to deliver literacy support specific to each students’ needs.
“The final frontiers in technology evolution is how these advancements can impact Healthcare and Education. We are now seeing these changes in real-time and look forward to becoming a global leader in the field of Education,” commented Adam Cegielski, CEO, Binovi Technologies
Binovi is a best-in-class neuro-visual performance platform designed to test, analyze, track, and report on individual cognitive performance. Binovi combines hardware, software, specialized expert knowledge, and unique data insights to deliver customized, one-on-one training and learning protocols ideal for K-12 Students, Vision Care Specialists, and Sports Performance testing and training. Designed for vision optimization and the enhancement of skills related to cognitive performance, Binovi provides measurable results in less time, and with less effort. Binovi is currently used in over 1,500 locations across 20 countries.
Certain statements contained in this news release constitute “forward-looking information” as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company’s financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company’s financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company’s continuous disclosure filings filed under the Company’s profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 4:09 PM on Tuesday, August 11th, 2020
Entered into a manufacturing and distribution agreement with Endless Sky Incorporated, a Canadian large scale Cannabis extractor based in Calgary, Alberta
Under the Agreement, ESI will serve as the exclusive distributor of Innocan’s CBD products in Canada under a license granted by Innocan. ESI will manufacture Innocan’s CBD products at ESI’s Health Canada licensed facility in Redvers, Saskatchewan.
ESI’s manufacturing and distribution rights consist of the Relief and Go CBD Spray and Cream and the SHIR Eye Serum, Face Cream and Night Cream.
Herzliya, Israel and Calgary, Alberta – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that its wholly owned subsidiary, Innocan Pharma Ltd. (“Innocan Israel”) has entered into a manufacturing and distribution agreement (the “Agreement”) with Endless Sky Incorporated (“ESI”), a Canadian large scale Cannabis extractor based in Calgary, Alberta.
Under the Agreement, ESI will serve as the exclusive distributor of Innocan’s CBD products in Canada under a license granted by Innocan. ESI will manufacture Innocan’s CBD products at ESI’s Health Canada licensed facility in Redvers, Saskatchewan. ESI’s manufacturing and distribution rights consist of the Relief and Go CBD Spray and Cream and the SHIR Eye Serum, Face Cream and Night Cream. The Agreement conditional upon ESI receiving Health Canada’s approval no later than December 31, 2020. According to the agreement, ESI shall pay Innocan Israel a cash license fee per Product as well as royalties based on net sales of the Products by ESI.
The Agreement is for a term of 12 months and will be automatically extended for additional periods of 12 months each based on ESI achieving minimum sales targets for the previous 12 months period.
ESI is responsible for meeting all Canadian regulations and registrations.
“Endless Sky is thrilled to exclusively manufacture and distribute Innocan’s SHIR Beauty & Science skin care line as well their Relief & Go topical products in Canada, with the future potential to access additional countries where cannabis regulations permit, and terms agreed by the parties. We believe that Innocan’s patent-pending, CBD-integrated products will be some of the highest quality CBD products to enter the market to date. Israel is well known as the global leader in CBD research and Innocan is leveraging that knowledge with a team of proven experts in the cosmetics, healthcare, sports medicine, and wellness markets. Innocan’s diligent commitment to research and development and its visionary thinking has positioned both companies to be market leaders in the CBD consumer packaged goods products space. The pharmaceutical expertise of Innocan together with Endless Sky’s large extraction capacity and manufacturing capabilities will combine to bring top of the line products to market at scale and price points that will allow for wide market access. This Agreement also positions both companies for CBD deregulation, allowing Endless Sky and Innocan’s CBD products to be further scaled through national retailers at such time. We are very excited to bring these products into the Canadian market in the very near future,” says CEO of Endless Sky, Travis George.
Iris Bincovich, Innocan’s Founder and CEO, commented: “We are thrilled to have found the right party to distribute and manufacture our CBD line of products in Canada. Distributing our CBD line of products is a significant milestone for us, given the importance of Canada to the world of CBD. Collaboration with Endless Sky, one of Canada’s largest extracting companies, will allow us to enter Innocan’s revolutionary wellness brands into the Canadian market”.
About Endless Sky Incorporated:
Endless Sky Incorporated is a Canadian large scale cannabis C02 extractor focusing on Cannabinoids. Endless Sky has a Health Canada standard processing licence which allows production of consumer packaged goods with Cannabinoids as an additive.
With top of market throughput, hemp genetics breeding program, strict QA/QC standards, and EU GMP design, Endless Sky is poised to be a global leader in low cost premium active pharmaceutical ingredients for the health, wellness and beauty markets.
About Innocan
The Company, through its wholly owned subsidiary, Innocan Pharma Ltd., is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”). Innocan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-Loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.
The Company signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release Liposome to be administrated by Injection. The Company plans, together with Prof. Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University to test the Liposome platform on several potential indications. The Company is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of InnoCan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.
For further information, please contact:
For Innocan Pharma Corporation: Iris Bincovich, CEO +972-54-3012842 [email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution regarding forward-looking information
Certain information set forth in this news release, including, without limitation, the effectiveness and safety of the Company’s products, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by InnoCan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact InnoCan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Posted by AGORACOM-JC
at 7:22 AM on Tuesday, August 11th, 2020
Baby Nutrition Paradigm shift: After 120 years, Else introduces a completely novel protein source for baby nutrition (over one year old) with a breakthrough, clean and sustainable production process.
Globally patented, and founded by infant nutrition industry veterans, Else Nutrition is the first dairy and soy- free, clean label, plant-based complete nutrition for babies (1 year and over).
A Revolution in the way babies are fed, Else Nutrition offers parents a great- tasting, dairy-free, soy-free and GMO-free alternative.
Else Plant-Based Complete Nutrition is now available for purchase at elsenutrition.com, U.S. shipping nationwide and to Canada.
VANCOUVER, BC / August 11, 2020 /ELSE NUTRITION HOLDINGS INC. (TSX-V:BABY)(OTCQX:BABYF) (FSE:0YL) (“Else” or the “Company“), today announces the online product launch of its Else Plant-Based Complete Toddler Nutrition, the first fully certified USDA Organic, Clean Label, Plant-Based, Soy-Free nutritional drink for toddlers. Made with ingredients, vitamins and minerals that help support growth and development after a baby’s first year. Else Plant-Based Complete Nutrition is the only globally-patented, real alternative for babies beyond the first year – including those with milk intolerances/sensitivities, those looking to avoid dairy and soy, and for all families looking for a clean, plant-based option for their children
Dairy-free, soy-free, corn syrup-free, gluten-free and non-GMO, Else Nutrition is a unique globally patented combination of whole-plant organic ingredients – almonds buckwheat and tapioca. This combination meets the gold standard equivalent of human milk nutritional composition values, based on WHO international standards, among others. Else Plant- Nutrition meets the strictest regulatory requirements and the highest nutrition standards, providing a full essential amino acid profile and a clean source of protein. It is manufactured in an infant grade U.S. manufacturing site and endorsed by a board of leading U.S. and international pediatricians and nutritionists.
“We are thrilled that today marks a huge leap forward in plant-based alternatives in the baby and toddler category,” said Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition. “For more than 120 years, cow’s milk and soy have dominated. After seven years of R&D, we are finally able to offer something else to parents and bring a real, clean label alternative to families across North America, so that they will never have to compromise on the health and nutrition of their toddler again.”
Else Plant-Based Complete Nutrition for Toddlers is minimally processed. Else intends for all its future products to meet this standard. With more than seven years of research and development, Else’s breakthrough process creates nutrition products from whole plants without altering their chemistry or using highly-processed extracts, or harsh chemicals. Through this disruptive process, Else is able to maximize the nutritional value andminimize environmental impact.
Additionally, Else Nutrition’s innovation pipeline includes a breakthrough, plant-based, clean label infant formula for babies 0-12 months. It is anticipated to launch in approximately two years, currently on its pathway for final FDA approval.
Beyond the brand’s Advisory Board of Pediatricians and nutritionists, Else has already captured the attention of many influential mothers, such as Hilaria Baldwin. As a mother of four with the fifth on the way, Hilaria came across Else as she searched for nutrition products for her toddler Romeo. After using the product, Hilaria decided to partner with Else to support its product launch.
Else Plant-Based Complete Nutrition for Toddlers is now available at elsenutrition.com, currently priced at $36 for a single 22 oz. powder canister and $136 for a 4-pack. The product will also be offered on Amazon.com later this month and in select retail chains sometime during Q4 2020.
Disruptive, ‘Beyond Organic’Production Process
Else products are minimally processed, using the cleanest production process in the infant nutrition industry. Else’s ‘Beyond Organic’ disruptive manufacturing process transforms whole plants to tasty toddler nutrition, without using highly-processed extracts or derivatives, harsh chemicals, or high-fructose corn syrup. Changing only the texture of the plants, and never the fundamental chemistry, allowing for more of the nutrients that nature intended to nourish the child.
Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc, is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.
For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.
Media Contact:
Covet Consumer Business Unit Gianna Totaro [email protected] P: 1-301-875-6574
Ms. Hamutal Yitzhak, CEO, Co-Founder & Director ELSE Nutrition Holdings Inc. E: [email protected] P: +972(0)3-6445095
Mr. Sokhie Puar, Director ELSE Nutrition Holdings Inc. E: [email protected] P: 604-603-7787
TSX Venture Exchange
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will,” “expect” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that listing on the FSE will create additional liquidity and attract additional investors in the European market. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Posted by AGORACOM-JC
at 7:18 AM on Tuesday, August 11th, 2020
Empower July 2020 patient volume surpasses 2,300 patients with Sun Valley Health increasing revenue per patient by 29%,
Adds 426 COVID-19 patient tests in July 2020 pilot testing program
VANCOUVER, BC / AUGUST 11, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (OTCQB:EPWCF) (Frankfurt:8EC) (“Empower” or the “Company“), a life sciences company, is pleased to announce the Company continues to execute on its plan to diversify revenue sources with 2,317 patient visits in July 2020 with record revenues coming from medical cannabis certifications, naturopathic consultations, product sales, identification card production and COVID-19 testing services.
“Diversification of revenue sources utilizing the strength of our clinic, physician, technology and operational assets has been a mission of ours.” said Steven McAuley, Chairman & CEO of Empower. “To see our team, deliver record performance in such a challenging environment, validates our execution strategy, validates the daily commitment of our team members and demonstrates we are on the right path to delivering significant shareholder value.”
The Arizona Department of Health Services announced yesterday its Phased Reopening Plan for Paused Industries indicating that community spread remains: Substantial based on the status of three main criteria: 1) Cases per 100,000 individuals: Substantial, 2) Percent positivity: Substantial, and 3) Hospital visits for COVID-like illnesses in the region: Substantial.
A dashboard available at azhealth.gov/businessCOVID19 indicates whether counties meet the recommended benchmarks for reopening of gyms, movie theaters, waterparks, tubing venues, and bars.
Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company conducts COVID-19 testing in its clinics under a four-phase national launch in the United States.
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley Chief Executive Officer
CONTACTS:
Investors: Steven McAuley Chairman & CEO [email protected] 604-789-2146
Investors: Dustin Klein SVP, Business Development [email protected] 720-352-1398
For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empowers patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
SOURCE: Empower Clinics Inc.
Tags: CBD, CSE, Dosed Movie, Dosed Wellness, Hemp, tsx Posted in Empower Clinics Inc., Featured | Comments Off on Empower $CBDT.ca #Covid19 Testing Growth Adds to Revenue Diversification with Record July 2020 Patient Visits and Record Revenue Per Patient $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca
Posted by AGORACOM-JC
at 8:11 PM on Monday, August 10th, 2020
Announced non-brokered private placement financing by issuance of 17,646,889 units at a price of $0.085 per Unit for gross proceeds of approximately $1,500,000
VANCOUVER, BC, Aug. 10, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 230 dispensaries throughout California and over 80 dispensaries throughout Arizona, is pleased to announce that it has closed its previously announced non-brokered private placement financing by issuance of 17,646,889 units (the “Units” and each individually, a “Unit“) at a price of $0.085 per Unit for gross proceeds of approximately $1,500,000 (the “Offering“).
Each Unit is comprised of one common share of the Company (a “Common Share“) and one Common Share purchase warrant. Each warrant will be exercisable into Share at a price of $0.10 until August 10, 2022.
The Company has paid eligible finders cash commission in the total amount of $108,201.26. The Company has also issued non-transferable compensation options (“Finder’s Options“) to finders to acquire up to a total of 1,272,959 Units (“Finder’s Units“), at a price of $0.085 per Finder’s Unit on or before August 10, 2022. Each Finder’s Unit will consist of one Share and one non-transferable share purchase warrant (the “Finder’s Warrant“). Each Finder’s Warrant will entitle the holder to purchase one Share at a price of $0.10 per Share on or before August 10, 2022.
All securities issued in connection with the Offering are subject to a statutory hold period of four-months and one day ending on December 11, 2020. The Company intends to use the net proceeds of the Offering for the expansion of Venom Extracts, Hollister’s 100% owned subsidiary, into California and for working capital and general corporate purposes.
About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
The securities issued in connection with the Offering have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “1933 Act“), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.
Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com
Posted by AGORACOM-JC
at 8:02 PM on Monday, August 10th, 2020
AGORACOM prides itself on becoming the discovery platform of emerging disruptive companies …. and we’ve discovered another one today in Vegaste Technologies, an e-commerce driven platform that is delivering all things plant-based to customers across Canada right now.
Vegaste has already started with both plant-based food meals directly to homes, thanks to partnerships right across the country – but isn’t stopping there as it adds hundreds of products to the platform. More than just lip service, Vegaste is already on a $US 3,000,000 run rate and that will probably accelerate in the coming months as marketing and additional products kick in.
Vegaste Founder, Sean Dollinger, is no stranger to AGORACOM followers as he was the Co-Founder behind wildly successful Namaste Technologies before it fell on hard times experienced by the cannabis industry. In addition to bringing back his immense e-commerce capabilities, he’s also implemented some valuable lessons learned at Namaste when it comes to corporate governance and share structure.
One of those lessons was appointing Julia Frank as CEO and giving her the team necessary to focus on doing the best job possible. Julia’s experience combines both start-up and big corporation structures thanks to being part of start-up teams within both BMW and Daimler in Germany.
Vegaste is hot off the listing press, so if you ever wanted to get a jump on your fellow investor it doesn’t get much fresher than this ….. unless you’re ordering a plant based meal off their platform at www.PlantX.com
If you believe in the paradigm shifting nature of plant based foods, be sure to watch and share this great interview with Vegaste CEO Julia Frank CEO & Founder Sean Dollinger.
Posted by AGORACOM-JC
at 3:35 PM on Monday, August 10th, 2020
Announced two webinars taking place on August 11th and 20th
Viewers can log on to RBMG’s live webinar at 4:30PM ET on Aug 11 (1:30PM PT)
Viewers can log on to SmallCap Power’s live webinar at 11:00AM ET on Aug 20th (8AM PT)
VANCOUVER, BC, Aug. 10, 2020 – Loop Insights Inc. (TSXV: MTRX) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement, and automated contact tracing to the brick and mortar space, announced two webinars taking place on August 11th and 20th through two esteemed investing firm platforms, SmallCap Power and RB Milestone Group (“RBMG”).
HOW TO REGISTER
Loop CEO Rob Anson will be providing an investor update on Loop’s current operations, its upcoming milestones, and how the Company is leveraging its technology for contactless, automated contact tracing to assist brick and mortar businesses reopen their doors in an expedited and safe manner during the pandemic
Viewers can log on to RBMG‘s live webinar at 4:30PM ET on Aug 11 (1:30PM PT).
A STRATEGIC MOVE TO INCREASE THE COMPANY‘S VISIBILITY EXPONENTIALLY
The Company will leverage the two firms’ large investor audiences to widen its visibility and diversify its investment portfolio. SmallCap Power is known to highlight young, innovative companies that have significant growth potential and offers an addressable investor audience of 3 million. RBMG offers Loop a proprietary database comprised of over 10,000 institutional investors, HNWs, UHNWs, family offices, brokers and research analysts throughout the US, setting the stage for Loop’s in-progress listing on the OTCQB® American Venture Market.
CEO Rob Anson explained: “There’s no greater time to become acquainted with Loop’s story and fully understand the scope of this investing opportunity. The company is gaining huge market traction. In July we traded more stocks than we have in this past year while being on the public market; and on July 17th, we saw a 100% increase in stock price. We are catching fire, and we want this to be known among the global investor community.”
About SmallCapPower: SmallCapPower is the industry’s leading and most trusted source for small-cap stock coverage, research, and analysis. Our investment philosophy is predicated on discovering smaller, underfollowed, and under researched public companies, which have significant growth potential.
About RBMG: Our US advisory practice delivers investor relations programs tailor-made for emerging companies who are private and publicly traded on the NYSE, NASDAQ, OTC, TSX, TSXV, CSE, ASX and AIM. It helps companies refine their communications strategies, weigh data, and advise clients on how to penetrate new markets.
About Loop Insights: Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia.
Forward-Looking Statements/Information:
This news release contains certain statements which constitute forward-looking statements or information. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
View original content to download multimedia: